Xiong Yujia, Li Mingxuan, Bai Jiwei, Sheng Yutao, Zhang Yazhuo
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Front Oncol. 2021 Apr 29;11:650534. doi: 10.3389/fonc.2021.650534. eCollection 2021.
Glioma is the most common primary intracranial malignant tumor in adults. Although there have been many efforts on potential targeted therapy of glioma, the patient's prognosis remains dismal. Methyltransferase Like 7B (METTL7B) has been found to affect the development of a variety of tumors. In this study, we collected RNA-seq data of glioma in CGGA and TCGA, analyzed them separately. Then, Kaplan-Meier survival analysis, univariate and multivariate Cox analysis, and receiver operating characteristic curve (ROC curve) analysis were used to evaluate the effect of METTL7B on prognosis. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA) enrichment analyses were used to identify the function or pathway associated with METTL7B. Moreover, the ESTIMATE algorithm, Cibersort algorithm, Spearman correlation analysis, and TIMER database were used to explore the relationship between METTL7B and immunity. Finally, the role of METTL7B was explored in glioma cells. We found that METTL7B is highly expressed in glioma, and high expression of METTL7B in glioma is associated with poor prognosis. In addition, there were significant differences in immune scores and immune cell infiltration between the two groups with different expression levels of METTL7B. Moreover, METTL7B was also correlated with immune checkpoints. Knockdown of METTL7B revealed that METTL7B promoted the progression of glioma cells. The above results indicate that METTL7B affects the prognosis of patients and is related to tumor immunity, speculating that METTL7B may be a new immune-related target for the treatment of glioma.
胶质瘤是成人中最常见的原发性颅内恶性肿瘤。尽管在胶质瘤的潜在靶向治疗方面已经做出了许多努力，但患者的预后仍然很差。已发现甲基转移酶样7B（METTL7B）会影响多种肿瘤的发展。在本研究中，我们收集了CGGA和TCGA中胶质瘤的RNA测序数据，并分别进行了分析。然后，使用Kaplan-Meier生存分析、单因素和多因素Cox分析以及受试者工作特征曲线（ROC曲线）分析来评估METTL7B对预后的影响。使用基因本体论（GO）、京都基因与基因组百科全书（KEGG）、基因集富集分析（GSEA）富集分析来确定与METTL7B相关的功能或途径。此外，使用ESTIMATE算法、Cibersort算法、Spearman相关性分析和TIMER数据库来探索METTL7B与免疫之间的关系。最后，在胶质瘤细胞中探索了METTL7B的作用。我们发现METTL7B在胶质瘤中高表达，并且胶质瘤中METTL7B的高表达与预后不良相关。此外，METTL7B表达水平不同的两组之间在免疫评分和免疫细胞浸润方面存在显著差异。此外，METTL7B还与免疫检查点相关。敲低METTL7B表明METTL7B促进了胶质瘤细胞的进展。上述结果表明，METTL7B影响患者的预后并与肿瘤免疫相关，推测METTL7B可能是治疗胶质瘤的一个新的免疫相关靶点。
